ストックスクリーナーアプリを入手
140.45
1.02%
1.42
プレマーケット:
140.87
0.42
+0.30%
前日終値:
$139.03
開ける：
$138.26
24時間の取引高:
6.45M
Relative Volume:
0.92
時価総額：
$174.33B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
20.71
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
+1.19%
1か月 パフォーマンス:
-3.13%
6か月 パフォーマンス:
+18.54%
1年 パフォーマンス:
+31.88%
1日の値動き範囲:
$137.60
$141.40
1週間の範囲:
$137.02
$142.97
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
140.45 | 172.51B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
922.50 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.10 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
210.26 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.38 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.96 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today - Yahoo! Finance Canada
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Gilead Sciences stock (US3755581036): Is HIV dominance still enough for long-term investor gains? - AD HOC NEWS
New U.S. foreign aid investment supports Gilead Sciences stock gains amid resistance at $141.64 - Traders Union
Gilead expands HIV prevention drug access to 3 million people - Investing.com
GILD Expands Access to HIV Prevention with New Investments - GuruFocus
Gilead Sciences stock edges higher as PEPFAR and Global Fund expand HIV medication access - Traders Union
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access - The Joplin Globe
Covington Team Leads Gilead Sciences $5B Acquisition of German Biotech - Law.com
Gilead (GILD), Tempus AI (TEM) expand multi-year oncology R&D collaboration - MSN
Patton Fund Management Inc. Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to buy clinical-stage biotech Tubulis for up to $5 billion - MSN
Gilead Sciences stock (US3755581036): Is HIV dominance still enough to drive future growth? - AD HOC NEWS
Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Given New $165.00 Price Target at Citigroup - MarketBeat
Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating - marketscreener.com
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration - Insider Monkey
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake - National Today
Greenup Street Wealth Management Boosts Gilead Sciences Stake - National Today
Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Firm Boosts Gilead Sciences Holdings - National Today
Robeco Institutional Asset Management B.V. Sells 108,349 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area - CSRwire
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy? - simplywall.st
Ritholtz Wealth Management Boosts Gilead Sciences Stake - National Today
Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Taxation With Representation: Goodwin, CMS, Wilson Sonsini - Law360
AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - MarketBeat
Gilead Sciences (GILD) Projects $107M Impact on Q1 Earnings from Recent Acquisitions - GuruFocus
Gilead projects $107M Q1 earnings headwind due to recent R&D deals - MSN
Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00 - MarketBeat
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $175 - Moomoo
Tempus AI stock rises on Gilead collaboration deal - Investing.com
Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Tempus AI stock rises on Gilead collaboration deal By Investing.com - Investing.com South Africa
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders - Yahoo Finance
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Why Is Tempus AI Stock Gaining Friday?Tempus AI (NASDAQ:TEM) - Benzinga
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline - Yahoo Finance
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Tempus AI expands collaboration with Gilead Sciences By Investing.com - Investing.com Australia
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
3.53%
0.84%
大文字化:
|
ボリューム (24 時間):